Eikon Therapeutics, Inc. (EIKN)
| Market Cap | 798.43M |
| Revenue (ttm) | n/a |
| Net Income | -318.91M |
| EPS | -113.67 |
| Shares Out | 53.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 78,655 |
| Open | 14.94 |
| Previous Close | 14.90 |
| Day's Range | 14.84 - 15.43 |
| 52-Week Range | 13.29 - 17.40 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About EIKN
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs using a platform that permits precise characterization of protein interactions in living cells. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-pen... [Read more]
Financial Performance
Financial StatementsNews
U.S. IPO Weekly Recap: 7 IPOs Make It One Of The Busiest Weeks In 4 Years
Seven IPOs and six SPACs priced this week. Five IPOs and five SPACs submitted filings. Five IPOs are currently scheduled in the week ahead, and some smaller issuers may join the calendar throughout th...
Eikon Therapeutics valued at $860 million in Nasdaq debut
Shares of drug developer Eikon Therapeutics opened 5.28% below their offer price in their Nasdaq debut on Thursday, valuing the company at about $860.3 million.
Perlmutter-backed Eikon Therapeutics raises $381.2 million in IPO
Drug developer Eikon Therapeutics said on Wednesday it had raised $381.2 million in its U.S. initial public offering, selling about 21.2 million shares priced at $18 apiece.
Eikon Therapeutics targets $908 million valuation in US IPO
Drug developer Eikon Therapeutics said on Wednesday it was targeting a valuation of up to $908.2 million in its U.S. initial public offering, as biotech listings make a comeback.
Eikon Therapeutics Launches IPO For Ambitious Oncology Pipeline Development
Eikon Therapeutics, Inc. is pursuing an IPO to fund its oncology pipeline, led by EIK1001 in Phase 2 trials for melanoma and NSCLC. EIKN's initial EIK1001 data show a 60% response rate, limited advers...
Biopharmaceutical firm Eikon Therapeutics files for US IPO
Clinical biopharmaceutical company Eikon Therapeutics on Friday filed for an initial public offering in the United States.
Eikon Therapeutics IPO Registration Document (S-1)
Eikon Therapeutics has filed to go public with an IPO on the NASDAQ
Immuno-responsive cancer biotech Eikon Therapeutics files for an estimated $300 million IPO
Eikon Therapeutics, a Phase 2 biotech developing therapies for immuno-responsive cancers, filed on Friday with the SEC to raise up to $100 million in an initial public offering. However, the deal size...